Seed, Pre-Seed
$250K – $2.5M
$300M
20+ companies
6 partners
Investment Thesis
Invests in innovative technologies and therapies for major global health challenges, including oncology and genetic therapies.
Meet the Team
Industry Focus
Invests In
Portfolio Companies (20)
2023
LimmaTech Biologics
"Discovered via firm_website (high confidence)"
Vaccine development company working to halt AMR and STI infections.
2022
Curevo Vaccine
"Discovered via firm_website (high confidence)"
Next-generation subunit vaccines, initially targeting varicella and shingles.
Memo Therapeutics
"Discovered via firm_website (high confidence)"
Antibody discovery platform, initially targeting Nipah virus, SARS-CoV-2, CMV and BKV.
2021
Antiva Biosciences
"Discovered via firm_website (high confidence)"
Novel non-surgical therapeutic candidate to treat pre-cancerous cervical lesions caused by HPV.
Pulmocide
"Discovered via firm_website (high confidence)"
Novel therapies for patients suffering from serious acute and chronic respiratory diseases.
Excision BioTherapeutics
"Discovered via firm_website (high confidence)"
CRISPR-based therapies for chronic viral infectious diseases such as HIV and hepatitis B.
2020
LakeShore Biopharma
"Discovered via firm_website (high confidence)"
LakeShore is scaling up undersupplied global health vaccines and developing new biologics.
ChromaCode
"Discovered via firm_website (high confidence)"
ChromaCode's HD-PCR technology enhances multiplexing capabilities on existing hardware.
Codagenix
"Discovered via firm_website (high confidence)"
Codagenix uses emerging computational and synthetic biology tools to rationally design vaccines.
54gene
"Discovered via firm_website (high confidence)"
54gene is using African genetic data to drive discoveries in drug and vaccine development.
Browse More Investors
Frequently Asked Questions
See if Adjuvant Capital is a match for your startup
Upload your pitch deck to see how well you match with Adjuvant Capital and 200+ other VC firms.